QSAR investigations on benzylideneamino and phenyliminomethyl scaffolds for selective COX-2 inhibition: A Hansch approach

Medicinal Chemistry

Volumn 5, Issue 5, 2009, Pages 440-445

  Manivannan, E ^a   Chaturvedi, S C ^a  

^a DEVI AHILYA UNIVERSITY   (India)

Author keywords

4 benzylideneamino; 4 phenyliminomethyl; Aryl sulfonamide; COX 1; COX 2; NSAIDs; QSAR; Selectivity

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; SULFONAMIDE;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HYDROPHOBICITY; IC 50; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

BENZYLIDENE COMPOUNDS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; IMINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; SULFONAMIDES;

EID: 70349122563     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609789117877     Document Type: Article

References (20)

1. Botting, J. H. Nonsteroidal antiinflammatory agents. Drugs Today, 1999, 35, 225-235.
2. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action of Asprin-like drugs. Nature (London), 1971, 231, 232-235.
3. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R.A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isaksen, P.; Stalling, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature (London), 1996, 384, 644-648.
4. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Doctor, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1, 5 diaryl pyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methyl phenyl)-3-(triflouro methyl)-1H-pyrazol-1-yl] benzene sulfonamide (SC-58635, Celecoxib). J. Med. Chem., 1997, 40, 1347-1365.
5. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O_Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I. W.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Young, R. N.; Zambani, R.; Boyce, S.; Rupniak, N.; Forest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 996, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor. Bioorg. Med. Chem. Lett., 1999, 9, 1773-1778.
6. Talley, J.J.; Brown, D.L.; Carter, J.S.; Graneto, M.J.; Koboldt, C. M.; Masferrer, J.L.; Perkins, W.E.; Rogers, D.J.; Shaffer, A.F.; Zhang, Y.Y.; Zweiefel, B.S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. J. Med. Chem., 2000, 43, 775-777.
7. Picot, D.; Loll, P.J.; Gravito, R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature, 1994, 367, 243-249.
8. Hawkey, C.J. COX-2 inhibitors. Lancet, 1999, 353, 307-314.
9. Chavatte, P.; Yous, S.; Marot, C.; Baurin, N.; Lesieur, D. Three-dimensional quantitative structure-activity relationships of cyclooxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis. J. Med. Chem., 2001, 44, 3223-3230.
10. Garg, R.; Kurup, A.; Mekapati, S. B.; Hansch, C. Cycloxygenase (COX) inhibitors: a comparative QSAR study. Chem.Rev., 2003, 103, 703-731.
11. Prasanna, S.; Manivannan, E.; Chaturvedi, S.C. Quantitative structure-activity relationship analysis of a series of 2,3-diaryl benzopyran analogues as novel selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 4005-4011.
12. Prasanna, S.; Manivannan, E; Chaturvedi, S.C. QSAR analysis of 2,3-diaryl benzopyrans/pyrans as selective COX-2 inhibitors based on semiempirical AM1 Calculations. QSAR Comb. Sci., 2004, 23, 621-628.
13. Prasanna, S.; Manivannan, E.; Chaturvedi, S.C. QSAR analysis of some fused pyrazoles as Cyclooxygenase inhibtors: a Hansch approach. Arch. Pharm. Pharm. Med. Chem., 2004, 337, 440-444.
14. Manivannan, E.; Prasanna, S.; Chaturvedi, S.C. Rationalization of physico-chemical properties of 5,6-diarylthiazolo [3,2-b]-1,2,4-triazoles towards cyclooxygenase-2 (COX-2) inhibition Indian J. Biochem. Biophy., 2004, 41, 179-183.
15. Prasanna, S.; Manivannan, E.; Chaturvedi, S.C. QSAR studies on structurally similar 2-(4-methanesulfonylphenyl) pyran-4-ones as selective COX-2 inhibitors: a Hansch approach. Bioorg. Med. Chem. Lett., 2005, 15, 313-320.
16. Prasanna, S.; Manivannan, E.; Chaturvedi SC. Quantitative structure-activity relationship analysis of 2,3 diaryl indoles as selective cyclooxygenase-2 inhibitors. J. Enzyme Inhib. Med. Chem., 2005, 20, 455-461.
17. Prasanna, S.; Manivannan, E.; Chaturvedi, S.C. Quantitative structure-activity relationship studies of cyclooxygenase inhibitors: a comprehensive analysis. Drug Dev. Res., 2005, 64, 220-231.
18. Lin, S-J.; Tsai, W-J.; Chiou, W-F.; Yang, T-H.; Yang, L-H. Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg. Med. Chem., 2008, 16, 2697-2706.
19. Hansch, C.; Leo, A. Substituents Constants for Correlation Analysis in Chemistry and Biology; John Wiley & Sons: New York, 1979.
20. Durbin, J.; Watson, G. S. Testing for serial correlation in least squares regression II. Biometrika, 1951, 38, 159-178.